TA
VRTX icon

Thor Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Thor Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$20K Buy
+86
New +$19.7K 1.05% 65
2019
Q1 		$37K Buy
+199
New +$36.8K 0.46% 104

Other funds holding VRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Thor Advisors's VRTX Position: Q1 2020 in Review

Thor Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2020: 86 shares worth $20K. The stake represents 1.05% of the portfolio and ranks #65 among its holdings. This is a return to the name: Thor Advisors previously reported a position in VRTX as recently as Q1 2019.

Thor Advisors first reported a position in VRTX in Q1 2019 and has held it in 2 quarters since. The position peaked at $37K in Q1 2019. 855 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

  • Thor Advisors held 86 shares of Vertex Pharmaceuticals worth $20K as of Q1 2020.
  • Vertex Pharmaceuticals was a new Thor Advisors position in Q1 2020.
  • Vertex Pharmaceuticals made up 1.05% of Thor Advisors's portfolio in Q1 2020, its #65 holding.
  • Thor Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 2 quarters since.
  • Thor Advisors's Vertex Pharmaceuticals position peaked at $37K in Q1 2019.
  • 855 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Thor Advisors's 13F filing for Q1 2020, filed 18 May 2020.